ZA992106B - Statin-MMP inhibitor combinations. - Google Patents

Statin-MMP inhibitor combinations.

Info

Publication number
ZA992106B
ZA992106B ZA9902106A ZA992106A ZA992106B ZA 992106 B ZA992106 B ZA 992106B ZA 9902106 A ZA9902106 A ZA 9902106A ZA 992106 A ZA992106 A ZA 992106A ZA 992106 B ZA992106 B ZA 992106B
Authority
ZA
South Africa
Prior art keywords
statin
mmp inhibitor
inhibitor combinations
combinations
mmp
Prior art date
Application number
ZA9902106A
Other languages
English (en)
Inventor
Roger Schofield Newton
Bruce David Roth
Original Assignee
Warner Lambert Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Warner Lambert Co filed Critical Warner Lambert Co
Publication of ZA992106B publication Critical patent/ZA992106B/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
ZA9902106A 1998-03-17 1999-03-16 Statin-MMP inhibitor combinations. ZA992106B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US7826598P 1998-03-17 1998-03-17

Publications (1)

Publication Number Publication Date
ZA992106B true ZA992106B (en) 1999-09-30

Family

ID=22142950

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA9902106A ZA992106B (en) 1998-03-17 1999-03-16 Statin-MMP inhibitor combinations.

Country Status (18)

Country Link
EP (1) EP1063991A1 (ko)
JP (1) JP2002506818A (ko)
KR (1) KR20010041916A (ko)
AR (1) AR018113A1 (ko)
AU (1) AU1591699A (ko)
BR (1) BR9815745A (ko)
CA (1) CA2309588A1 (ko)
CO (1) CO5070670A1 (ko)
GT (1) GT199900039A (ko)
HN (1) HN1999000029A (ko)
MY (1) MY140504A (ko)
NZ (1) NZ505994A (ko)
PA (1) PA8469001A1 (ko)
PE (1) PE20000348A1 (ko)
SV (1) SV1999000026A (ko)
UY (1) UY25436A1 (ko)
WO (1) WO1999047138A1 (ko)
ZA (1) ZA992106B (ko)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0100761D0 (en) 2001-01-11 2001-02-21 Biocompatibles Ltd Drug delivery from stents
RU2410118C2 (ru) 2004-12-15 2011-01-27 Зольвай Фармасьютиклз Гмбх ФАРМАЦЕВТИЧЕСКИЕ КОМПОЗИЦИИ, ВКЛЮЧАЮЩИЕ ИНГИБИТОРЫ НЭП (НЕЙТРАЛЬНОЙ ЭНДОПЕПТИДАЗЫ), ИНГИБИТОРЫ ЭНДОГЕННОЙ ПРОДУЦИРУЮЩЕЙ ЭНДОТЕЛИН СИСТЕМЫ И ИНГИБИТОРЫ ГМГ (ГИДРОКСИМЕТИЛГЛУТАРИЛ)СоА РЕДУКТАЗЫ
SG166829A1 (en) * 2005-11-08 2010-12-29 Ranbaxy Lab Ltd Process for (3r, 5r)-7-[2-(4-fluorophenyl)-5-isopropyl-3-phenyl-4- [(4-hydroxy methyl phenyl amino) carbonyl]-pyrrol-1-yl]-3, 5-dihydroxy-heptanoic acid hemi calcium salt
WO2010005389A1 (en) * 2008-07-11 2010-01-14 Forskarpatent I Syd Ab Oxidized ldl specific antibody-fusion and conjugated proteins

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR9611410A (pt) * 1995-11-02 1999-01-05 Warner Lambert Co Método e composição farmacêutica para regular a concentração de lipídios
PL186416B1 (pl) * 1996-05-17 2004-01-30 Warner Lambert Co Związek bifenylosulfonamidowy i preparat farmaceutyczny zawierający ten związek
IL128545A0 (en) * 1996-12-09 2000-01-31 Warner Lambert Co Method for treating and preventing heart failure and ventricular dilatation
TW536540B (en) * 1997-01-30 2003-06-11 Bristol Myers Squibb Co Endothelin antagonists: N-[[2'-[[(4,5-dimethyl-3-isoxazolyl)amino]sulfonyl]-4-(2-oxazolyl)[1,1'-biphenyl]-2-yl]methyl]-N,3,3-trimethylbutanamide and N-(4,5-dimethyl-3-isoxazolyl)-2'-[(3,3-dimethyl-2-oxo-1-pyrrolidinyl)methyl]-4'-(2-oxazolyl)[1,1'-biphe
GT199800126A (es) * 1997-08-29 2000-01-29 Terapia de combinacion.

Also Published As

Publication number Publication date
PA8469001A1 (es) 2002-09-17
AU1591699A (en) 1999-10-11
CA2309588A1 (en) 1999-09-23
BR9815745A (pt) 2000-11-14
NZ505994A (en) 2003-10-31
JP2002506818A (ja) 2002-03-05
SV1999000026A (es) 2000-01-18
UY25436A1 (es) 2001-10-25
CO5070670A1 (es) 2001-08-28
GT199900039A (es) 2000-09-06
HN1999000029A (es) 1999-09-29
KR20010041916A (ko) 2001-05-25
MY140504A (en) 2009-12-31
AR018113A1 (es) 2001-10-31
WO1999047138A1 (en) 1999-09-23
EP1063991A1 (en) 2001-01-03
PE20000348A1 (es) 2000-05-22

Similar Documents

Publication Publication Date Title
ZA996185B (en) Sulfanylsilanes.
ZA200005136B (en) Dihydropyrimides.
EG24814A (en) Novel compounds.
HK1036101A1 (en) Refrigerator.
HK1040253A1 (en) Factor viia inhibitors.
ZA99254B (en) Benzosulfone derivatives.
ZA991975B (en) Enzyme inhibitors.
HK1022000A1 (en) Iron.
ZA991272B (en) Novel thiobenzamides.
ZA9811794B (en) Ace inhibitor-MMP inhibitor combinations.
ZA992443B (en) Hydroxy-methyl-hexanones.
ZA991550B (en) Cyclohexanediole derivatives.
ZA992572B (en) Spirit chiller.
ZA995325B (en) Methylcyclotetradec-5-en-1-ones.
ZA993123B (en) Trisresorcinyltriazines.
ZA200007405B (en) Angiogenesis inhibitors.
ZA992899B (en) Novel compound.
HK1021879A1 (en) Carrying case.
ZA992106B (en) Statin-MMP inhibitor combinations.
ZA994289B (en) Cyclooxygenase inhibitor.
HK1028588A1 (en) Case.
ZA99985B (en) New compound.
ZA99925B (en) Composition.
HK1062445A1 (en) B-secretase inhibitor.
ZA991761B (en) New agent.